$-0.01 EPS Expected for Neovasc Inc. (NVCN); Merrill Lynch Life Variable Annuity Separate Account C (PFG) Sentiment Is 1.18

February 28, 2018 - By Winifred Garcia

Analysts expect Neovasc Inc. (NASDAQ:NVCN) to report $-0.01 EPS on March, 22.They anticipate $0.48 EPS change or 102.13% from last quarter’s $0.47 EPS. After having $-0.06 EPS previously, Neovasc Inc.’s analysts see -83.33% EPS growth. The stock decreased 11.59% or $0.02 during the last trading session, reaching $0.19. About 5.43M shares traded or 210.94% up from the average. Neovasc Inc. (NASDAQ:NVCN) has declined 19.02% since February 28, 2017 and is downtrending. It has underperformed by 35.72% the S&P500.

Principal Financial Group, Inc. provides retirement, asset management, and insurance services and products to businesses, individuals, and institutional clients worldwide. The company has market cap of $18.41 billion. It operates through Retirement and Income Solutions, Principal Global Investors, Principal International, and U.S. It has a 8.07 P/E ratio. Insurance Solutions divisions.

Among 3 analysts covering Neovasc (NASDAQ:NVCN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Neovasc had 7 analyst reports since August 12, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, August 25 by Canaccord Genuity. The firm earned “Buy” rating on Thursday, December 10 by Ladenburg Thalmann. The rating was downgraded by Zacks on Wednesday, August 12 to “Buy”. As per Friday, May 20, the company rating was downgraded by Ladenburg Thalmann. The firm has “Hold” rating given on Wednesday, August 26 by Zacks. The firm earned “Market Outperform” rating on Wednesday, October 7 by JMP Securities.

Neovasc Inc., a specialty medical device company, develops, makes, and markets cardiovascular devices worldwide. The company has market cap of $19.41 million. The Company’s products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. It has a 0.75 P/E ratio. The firm also provides Peripatch biological tissue products that are used as components in third-party medical products, such as transcatheter heart valves for industry partners and other customers.

Since January 1, 0001, it had 0 buys, and 12 sales for $27.50 million activity.

Nippon Life Insurance Co holds 21.91% of its portfolio in Principal Financial Group, Inc. for 18.14 million shares. Capital Management Corp Va owns 237,343 shares or 4.36% of their US portfolio. Moreover, Iowa State Bank has 2.88% invested in the company for 95,024 shares. The Minnesota-based Tealwood Asset Management Inc has invested 2.5% in the stock. North Star Asset Management Inc, a Wisconsin-based fund reported 330,344 shares.

Ratings analysis reveals 25% of Principal Fincl’s analysts are positive. Out of 4 Wall Street analysts rating Principal Fincl, 1 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. The lowest target is $57.0 while the high is $61.0. The stock’s average target of $59 is -7.19% below today’s ($63.57) share price. PFG was included in 4 notes of analysts from October 7, 2016. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, November 17 report. The stock has “Equal Weight” rating by Barclays Capital on Thursday, November 17. As per Friday, October 7, the company rating was initiated by Credit Suisse. Citigroup initiated Principal Financial Group, Inc. (NASDAQ:PFG) on Thursday, January 26 with “Neutral” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: